Dr. Schneider is executive vice president and chief clinical development and operations officer of Ionis Pharmaceuticals. As a member of our executive leadership team, Dr. Schneider oversees all stages of clinical development of Ionis’ antisense medicines across the company’s therapeutic franchises. Dr. Schneider joined Ionis in December 2013 as executive director, clinical development and became vice president, clinical development, severe and rare diseases in April 2015, senior vice president, head of clinical development in August 2018 and executive vice president, chief clinical development officer in January 2021.
Dr. Schneider has two decades of experience in clinical development primarily in the rare diseases space. Prior to joining Ionis, Dr. Schneider was senior medical director at both Synageva BioPharma and Biovail Technologies Ltd.
Dr. Schneider received his medical degree from University of Medicine and Dentistry of New Jersey and completed his training in Pediatric and Adolescent Medicine at Robert Wood Johnson University Hospital in New Brunswick, New Jersey.